Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03710642 · ClinicalTrials.gov registry record · Phase 2
Prazosin for Agitation in Alzheimer's Disease
A Phase 2 study, sponsored by Alzheimer's Disease Cooperative Study (ADCS).
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT03710642 is a Phase 2 study that has completed, run by Alzheimer's Disease Cooperative Study (ADCS). The registered enrollment target is 35 participants.
The verdict
NCT03710642, a Phase 2 study, has completed, sponsored by Alzheimer's Disease Cooperative Study (ADCS).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
The study evaluates the effects of Prazosin on agitation in adults with Alzheimer's disease. Two thirds of the participants will participate in the medication portion, while one third will participate in the placebo portion
Interventions
- DRUG Placebo oral capsule
- DRUG Prazosin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2018-10-23 |
| Est. Completion | 2022-01-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03710642
The ClinicalTrials.gov registry entry for NCT03710642 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alzheimer's Disease Cooperative Study (ADCS), which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03710642 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03710642 about?
NCT03710642 is a clinical study titled "Prazosin for Agitation in Alzheimer's Disease". The study evaluates the effects of Prazosin on agitation in adults with Alzheimer's disease. Two thirds of the participants will participate in the medication portion, while one third will participate in the placebo portion
What is the current status of trial NCT03710642?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2018-10-23. Estimated completion is 2022-01-05.
What interventions are being tested in trial NCT03710642?
The interventions under investigation include: Placebo oral capsule (DRUG), Prazosin (DRUG).
Who is sponsoring clinical trial NCT03710642?
This trial is sponsored by Alzheimer's Disease Cooperative Study (ADCS), which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.